InvestorWire NewsRoom

InvestorNewsBreaks

NewsBreak Category: Biotechnology
Thursday Mar 16, 2023 - 3:04 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring. The event is slated to take place from March 20–22, 2023, in Basel, Switzerland, and draw over 2,800 executives from biotech, pharma and finance…

Continue Reading

Wednesday Mar 15, 2023 - 1:29 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. In collaboration with Experimur, a Frontage Laboratories company, Silo Pharma tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen…

Continue Reading

Wednesday Mar 15, 2023 - 10:14 am

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Expands EU DuoPack Agreement by Including Insulin as Eligible Drug

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, has added insulin onto the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited (“MSWDL”). Last September, Nemaura and MSWDL announced a commercial agreement making NMRD’s non-invasive wearable skin patch sensors available as a MySugarWatch-branded…

Continue Reading

Tuesday Mar 14, 2023 - 1:19 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Acquires LIVEMOR Assets

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has acquired substantially all assets from LIVMOR, a digital health solutions company. Specifically, LIVMOR offers a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition allows HeartBeam to extend its reach with LIVEMOR’s FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and…

Continue Reading

Tuesday Mar 14, 2023 - 12:41 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that it has renewed the service agreement with ShareIntel-Shareholder Intelligence Services LLC (www.ShareIntel.com). Under the agreement, ShareIntel will assist in ongoing investigations related to suspected naked short selling of FSD Pharma’s…

Continue Reading

Monday Mar 13, 2023 - 2:36 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) On Track to Advance Innovative Products

HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG…

Continue Reading

Friday Mar 10, 2023 - 1:19 pm

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to…

Continue Reading

Thursday Mar 09, 2023 - 11:23 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form…

Continue Reading

Wednesday Mar 08, 2023 - 12:23 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Makes Changes in Senior Leadership Roles

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has made key leadership changes. The company announced that HeartBeam president Robert Eno has been appointed executive vice president while current chief business officer Jon Hunt, PhD, will transition into the role of strategic advisor and consultant, effective March 15, 2023.…

Continue Reading

Wednesday Mar 08, 2023 - 11:31 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, wellness, science and technology sectors. She has proven expertise in…

Continue Reading

Wednesday Mar 08, 2023 - 10:27 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, at 12:40 p.m. ET. Interested parties should visit https://ibn.fm/4Qlqa to register for and access…

Continue Reading

Wednesday Mar 08, 2023 - 9:52 am

InvestorNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug

Unicycive (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, has announced its entry into a securities purchase agreement with certain health care-focused institutional investors that will provide up to $130 million in gross proceeds to Unicycive through a private placement. According to the announcement, the private placement includes initial upfront funding of $30 million. Vivo Capital is leading the funding…

Continue Reading

Tuesday Mar 07, 2023 - 11:45 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Clinical Trial of Jellyfish Sting Prevention Sunscreen on Man-O-War

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, has launched a clinical trial designed to explore the effectiveness of an improved formulation of NoStingz jellyfish sting prevention sunscreen against man-o-war jellyfish. The trial, which will be led by Dr. Patric Rice and Dr. Eric Stroud, will be conducted by Angelshark Consulting; the trial will take place in the Florida…

Continue Reading

Monday Mar 06, 2023 - 1:00 pm

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced debt settlements. According to the announcement, the company announced settlements for debt owed to some arms-length creditors, service providers and debtors of the company. The company noted that…

Continue Reading

Monday Mar 06, 2023 - 9:54 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. BiondVax CEO Amir Reichman is a guest of the popular on-demand podcast,…

Continue Reading

Friday Mar 03, 2023 - 2:47 pm

InvestorNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Receives Notice of Third US Patent Related to ThermoStem IP

BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, has received a notice of allowance for the patent application relating to its metabolic ThermoStem(R) program. The notice, dated Feb. 24, 2023, came from the United States Patent and Trademark Office. This marks the third patent approved relating to this specific group of intellectual property, the company noted; the new patent covers three-dimensional scaffolds and…

Continue Reading

Friday Mar 03, 2023 - 1:18 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15 formulation by the U.S. Patent and Trademark Office (“USPTO”). “The patent, titled ‘Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females’, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions. SPC-15 is a targeted…

Continue Reading

Friday Mar 03, 2023 - 1:06 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), Collaborators Positioned to Rapidly Develop Neutralizing NanoAbs for Emerging COVID-19 Variants

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products, is working on changing the grim reality caused by the evolution of COVID-19. “The company’s leading inhaled nanosized antibody (‘NanoAb’) candidate, which is currently being prepared for clinical trials, has shown neutralization of all relevant Omicron subvariants… Developed in collaboration with Germany-based Max Planck Institute for Multidisciplinary Sciences (‘MPI’) and…

Continue Reading

Friday Mar 03, 2023 - 11:23 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Retains Top Banking Firm to Support Growth, Revenue-Generating Strategy

Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG will be supporting Aditxt’s strategic growth and revenue generating plans for its subsidiary Pearsanta Inc., as well as other Aditxt programs. The company noted that…

Continue Reading

Friday Mar 03, 2023 - 9:26 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds: Innovations in Consciousness, Psychedelics & Mental Health.” The SXSW event is slated for March 10–19, 2023, and will be held in Austin, Texas. The panel that Drysdale and…

Continue Reading

Thursday Mar 02, 2023 - 1:02 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Q4 and FY 2022 Results Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, today announced its plans to host a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2022. The call is scheduled to start at 4:30 p.m. Eastern Time on Thursday, March 16, 2023.…

Continue Reading

Wednesday Mar 01, 2023 - 12:32 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) News Discussed in Latest InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, was featured in a recent InvestmentPitch Media video release. The video focused on FSD Pharma’s recent announcement that entrepreneur Kevin Harrington was joining its advisory board. According to the announcement, Harrington, the inventor…

Continue Reading

Tuesday Feb 28, 2023 - 11:19 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that iconic entrepreneur Kevin Harrington has joined its advisory board. Harrington is world renowned as the inventor of the informercial, pioneer of the “As Seen on TV” brand, and one of…

Continue Reading

Thursday Feb 23, 2023 - 9:38 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and long-term milestones. A part of that plan was the release of an estimated 15% of Cybin’s workforce, including those in roles that were identified as not a clinical priority…

Continue Reading

Tuesday Feb 21, 2023 - 2:32 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Recent “Authority” Magazine Interview

HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, is featured in a recent interview with David Leichner that was published in “Authority” magazine. The interview was one of a series of interviews with leaders of tech companies. The series, called “Technology Making an Important Positive Social Impact,” spotlights companies working on making monumental positive changes to society, health, and the environment. In the interview,…

Continue Reading

Tuesday Feb 21, 2023 - 10:21 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participation in the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2023 Forum taking place from Feb. 23-25 in San Diego, California, at the Marriott…

Continue Reading

Friday Feb 17, 2023 - 12:21 pm

InvestorNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD

Psycheceutical Bioscience (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian-based contract research organization. The agreement calls for iNGENū to conduct ​two human ​clinical trials of BWVI’s patented NeuroDirect(TM) ketamine topical ​in Australia. The first, a phase 1 trial, is designed to study 20 people and…

Continue Reading

Thursday Feb 16, 2023 - 3:43 pm

InvestorNewsBreaks – Aesther Healthcare Acquisition Corp. and Ocean Biomedical Inc. (NASDAQ: OCEA) Announce Approved Business Combination

Aesther, a special purpose acquisition company (“SPAC”) and Ocean Biomedical Inc. (NASDAQ: OCEA), a next-generation biopharma company, recently announced stockholder approval of all proposals related to the previously disclosed proposed business combination between Aesther and Ocean. According to the update, the approvals were secured at a special meeting of stockholders held on Feb. 3, 2023. The combined company, Ocean Biomedical, and its Class A common…

Continue Reading

Wednesday Feb 15, 2023 - 3:28 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Looking to Achieve ‘Big Things’ in 2023

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. “MetAlert is looking to achieve ‘some big things’ in 2023. Speaking in an interview with Sequire Spotlight published Dec. 28, CEO Patrick Bertagna outlined the company’s strategic plans for 2023. MetAlert, he explained, is ‘looking at making some acquisitions, bringing on some new products, and possibly…

Continue Reading

Wednesday Feb 15, 2023 - 1:27 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently achieved key milestones. These include the demonstration of statistically significant positive results from a preclinical in-vivo proof-of-concept study of its inhaled anti-COVID-19 nanosized antibodies (“NanoAbs”). “Its lead NanoAb candidate, designed to treat COVID-19, has exhibited significant competitive advantages over existing…

Continue Reading

Wednesday Feb 15, 2023 - 11:37 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it is in compliance with the minimum bid price requirement of $1 per…

Continue Reading

Tuesday Feb 14, 2023 - 12:45 pm

InvestorNewsBreaks – IBN to Shine the Spotlight on Health Equity in Clinical Trials Congress

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with Kisaco Research for its upcoming Health Equity in Clinical Trials Congress, which is slated to take place at the beautiful Hilton Boston Back Bay on Feb. 22-23, 2023. Kisaco is a leader in combining state-of-the-art conference production with high-impact networking to drive conversations between marquee organizations, policymakers, academic institutions, medtech…

Continue Reading

Tuesday Feb 14, 2023 - 11:01 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will…

Continue Reading

Tuesday Feb 14, 2023 - 10:31 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit…

Continue Reading

Monday Feb 13, 2023 - 11:19 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application for the use of its central nervous system (“CNS”) homing peptides to treat Alzheimer’s disease and the onset of dementia. Alzheimer’s has proven to be a progressive neurodegenerative disorder associated with the destruction of higher brain structures, such…

Continue Reading

Thursday Feb 09, 2023 - 10:51 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Canada. That letter and what it means was the focus of a recent InvestmentPitch Media video. In the video, InvestmentPitch Media’s Cassandra Bolinski discusses the…

Continue Reading

Wednesday Feb 08, 2023 - 2:24 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Pushing Boundaries of Innovation

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, developed GPS SmartSole(R), a medical monitoring device integrated into an orthotic insole, facilitating discreet tracking and remote monitoring of those living with Alzheimer’s, dementia and autism, who have a tendency to wander and become lost. “The SmartSole enables tracking by utilizing a 4G cellular network and … can be configured to…

Continue Reading

Wednesday Feb 08, 2023 - 12:43 pm

InvestorNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program

BioRestorative Therapies (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem(R) program. “Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the company’s CEO. “We are committed…

Continue Reading

Wednesday Feb 08, 2023 - 10:37 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate…

Continue Reading

Tuesday Feb 07, 2023 - 1:53 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).